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Abstract
Ambulatory blood pressure monitoring (ABPM) can detect phenotypes associated with increased 
cardiovascular disease (CVD) risk. Diabetes is associated with increased CVD risk but few data 
are available documenting whether blood pressure (BP) phenotypes, detected by ABPM, differ 
between individuals with versus without diabetes. We conducted a cross-sectional analysis of 567 
participants in the Jackson Heart Study, a population-based study of African Americans, taking 
antihypertensive medication to evaluate the association between diabetes and ABPM phenotypes. 
Two clinic BP measurements were taken at baseline following a standardized protocol. ABPM was 
performed for 24 hours following the clinic visit. ABPM phenotypes included daytime, sustained, 
nocturnal, and isolated nocturnal hypertension, a non-dipping BP pattern, and white coat, masked, 
and masked isolated nocturnal hypertension. Diabetes was defined as fasting glucose ≥126 mg/dL, 
hemoglobin A1c ≥6.5% (48 mmol/mol), or use of insulin or oral hypoglycemic medications. Of 
the included participants (mean age 62.3 years, 71.8% female), 196 (34.6%) had diabetes. After 
multivariable adjustment, participants with diabetes were more likely to have daytime 
hypertension (prevalence ratio [PR]: 1.32; 95% CI: 1.09–1.60), masked hypertension (PR: 1.46; 
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95% CI: 1.11–1.93), and masked isolated nocturnal hypertension (PR: 1.39; 95% CI: 1.02–1.89). 
Although nocturnal hypertension was more common among participants with versus without 
diabetes, this association was not present after adjustment for daytime systolic BP. Diabetes was 
not associated with the other ABPM phenotypes investigated. This study highlights the high 
prevalence of ABPM phenotypes among individuals with diabetes taking antihypertensive 
medication.
Elevated blood pressure (BP) measured in the clinic setting is a well-established risk factor 
for cardiovascular disease (CVD) and end-stage renal disease among the general population 
as well as individuals with diabetes.1–4 Compared with measurements taken in the clinic 
setting, ambulatory blood pressure monitoring (ABPM) may provide a better estimate of an 
individual’s average BP.5,6 Also, a mismatch can exist between hypertension defined using 
clinic-measured BP and BP measured outside of the clinic setting. For example, some 
individuals with elevated clinic BP may have non-elevated BP when measured outside of the 
clinic setting by ABPM (i.e., white coat hypertension).5–8 The opposite also occurs; some 
individuals with non-elevated clinic BP may have elevated BP when measured outside of the 
clinic setting (i.e., masked hypertension).5–8 ABPM can also identify diurnal BP patterns, 
including BP that does not decline normally at night (non-dipping BP) and elevated BP at 
night (nocturnal hypertension).5,6 Several of these phenotypes, including elevated mean 24-
hour BP, elevated nighttime BP, and non-dipping BP pattern have been associated with 
increased CVD risk.5,9,10
A recent study reported that individuals with versus without diabetes were more likely to 
have a higher daytime, and nighttime systolic BP (SBP) assessed by ABPM.11 However, this 
study only included individuals with a clinical indication for ABPM, the results were not 
adjusted for potential confounders, it was conducted in a population of both treated and 
untreated individuals analyzed together, and did not include African Americans. A high 
prevalence of abnormal BP phenotypes identified using ABPM among individuals with 
diabetes may indicate a role for ABPM to guide treatment of hypertension in this population. 
The objective of this study was to compare the prevalence of ABPM phenotypes among 
individuals with and without diabetes in a population-based cohort of African American 
adults taking antihypertensive medication. Phenotypes evaluated included out-of-office BP 
(daytime hypertension, sustained hypertension), diurnal BP patterns (nocturnal hypertension, 
isolated nocturnal hypertension, non-dipping pattern) and mismatches between clinic and 
out-of-clinic BP (white coat hypertension, masked hypertension, and masked isolated 
nocturnal hypertension).
RESEARCH DESIGN AND METHODS
Study Population
The Jackson Heart Study (JHS) is a population-based study designed to examine CVD risk 
factors in African-American men and women. Participants were recruited from urban and 
rural areas of 3 counties (Hinds, Madison, and Rankin) that comprise the Jackson, 
Mississippi metropolitan area. Details of the design and conduct of the JHS have been 
published previously.12,13 The study enrolled 5,301 African Americans between 2000 and 
Bromfield et al. Page 2





















2004. Participants were invited to complete a 24-hour ABPM session at baseline, which 
1,146 volunteers completed. For the current analysis, we excluded participants with an 
incomplete ABPM reading (n=100), missing clinic SBP (n=5), missing diabetes status 
(n=9), and missing (n=58) or not taking antihypertensive medication (n=407) for a final 
sample size of 567 participants. We restricted the analyses to participants taking 
antihypertensive medication as there were too few participants with diabetes not taking 
antihypertensive medication (n=51) to perform analyses in this group. The protocol for the 
JHS was approved by the institutional review boards at the participating institutions, 
including Jackson State University, Tougaloo College, and University of Mississippi Medical 
Center, and all participants provided written informed consent. The analyses of the data that 
we report were approved by the institutional review board at the University of Alabama at 
Birmingham.
Data Collection
Data for the current analyses were collected by questionnaire, a clinic examination and 
ABPM. Data collected through the interview-administered questionnaire included age, sex, 
education, marital status, current smoking, physical activity, history of stroke and 
myocardial infarction, and self-reported use of antihypertensive medication. Using a 
modified Baecke questionnaire, duration, frequency and intensity of physical activity were 
reported in four domains (active living, work, home life and sports and exercise).14,15 
Participants were considered to be taking antihypertensive medication if they self-reported 
use of medication to lower BP in the 2 weeks prior to their clinic visit. The names of all 
classes of antihypertensive medication being taken in the 2 weeks prior to the clinic visit 
were recorded at baseline during a pill bottle review. During the clinic examination, trained 
technicians measured height, weight, and BP. Measured height and weight were used to 
calculate body mass index (BMI).
Participants were asked to fast overnight prior to their JHS examination. Venipuncture was 
done after participants were in a supine position for 20 minutes. Blood was collected within 
a designated one-hour time window following a standardized protocol. Total and HDL-
cholesterol, serum glucose, and hemoglobin A1c (HbA1c) were measured from blood 
samples taken during the clinic examination. Total and HDL-cholesterol were measured 
using a Roche COBAS Fara analyzer in the central laboratory, located at the University of 
Minnesota Department of Laboratory Medicine and Pathology. Fasting serum glucose was 
measured using a glucose oxidase method on a Vitros 950 or 250 analyzer at the University 
of Mississippi Medical Center. HbA1c was measured using a TOSOH high performance 
liquid chromatography system in the central laboratory at the University of Minnesota. 
Diabetes was defined as fasting plasma glucose ≥ 126 mg/dL, HbA1c ≥ 6.5% (48 mmol/
mol), or use of insulin or other glucose lowering medications within 2 weeks prior to the 
clinic visit.
Clinic BP Measurements—Clinic BP was measured at baseline following a standardized 
protocol using a Hawksley random zero sphygmomanometer (RZS) and Littman 
stethoscope. The appropriate cuff size was determined by measuring each participant’s arm 
circumference. Two BP readings were obtained after 5 minutes of seated rest with a one-
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minute rest between measurements. The mean of these measurements was used to define 
clinic SBP and diastolic BP (DBP).
Ambulatory BP Measurements—ABPM was performed following the clinic 
examination using a SpaceLabs 90207 device. This device uses oscillometry to measure BP 
and automatically adjusts the level of the cuff inflation based on the participant’s SBP. Cuff 
sizes were selected after measuring participants’ non-dominant arm circumference. 
Measurements were taken every 20 minutes during the 24-hour monitoring period. After 24 
hours of monitoring, participants returned to the JHS Examination Center to have the device 
removed. Consistent with the International Database of Ambulatory Blood Pressure and 
Cardiovascular Disease (IDACO), daytime was defined as 10 am to 8 pm and nighttime was 
defined as 12 am to 6 am.16 For an ABPM measurement to be considered complete, a 
participant was required to have at least 10 daytime and 5 nighttime SBP and DBP 
measurements. On average, participants with complete ABPM had 23 daytime 
measurements and 17 nighttime measurements.
BP Phenotypes—Elevated clinic BP was defined as mean clinic SBP ≥ 140 mmHg or 
DBP ≥ 90 mmHg; elevated daytime BP as mean daytime SBP ≥ 135 mmHg or DBP ≥ 85 
mmHg; and elevated nighttime BP as mean nighttime SBP ≥ 120 mmHg or DBP ≥ 70 
mmHg 17. Using clinic BP and ABPM, we evaluated three phenotype domains: elevated 
mean clinic and/or daytime BP, diurnal BP patterns, and a mismatch between clinical 
hypertension and out-of-clinic hypertension (Table 1). Elevated mean clinic and/or daytime 
BP phenotypes included clinic hypertension, daytime hypertension, and sustained 
hypertension. Diurnal BP patterns included nocturnal hypertension, isolated nocturnal 
hypertension, and a non-dipping BP pattern. Mismatches between clinical hypertension and 
out-of-clinic hypertension included white coat hypertension, masked hypertension, and 
masked isolated nocturnal hypertension.
BP Comparability Study—A Blood Pressure Comparability Study was conducted after 
the transition from the use of a Hawksley RZS to an Omron automatic oscillatory device 
(AOD) in the second clinic visit. Two technicians took two BP measurements 
simultaneously using a Y connector and double-headed stethoscope with the RZS and AOD 
devices, separately. BP measurements obtained at baseline with the RZS were calibrated to 
measurements obtained with the AOD device using the following calibration equations to 
predict SBP and DBP:
This equation modeled the difference between the AOD and RZS as a function of RZS.
Statistical Analysis
Characteristics were calculated for participants with and without diabetes, separately, and 
compared using t-tests and chi-square tests as appropriate. The prevalence of clinic 
hypertension and BP phenotypes assessed by ABPM was calculated for participants with 
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and without diabetes and were compared using chi-square tests. Binomial regression models 
were used to calculate prevalence ratios (PR) for each BP phenotype assessed by ABPM 
comparing participants with versus without diabetes. Models with progressive adjustment 
were fitted. Model 1 adjusted for age and sex. Model 2 included additional adjustment for 
education, marital status, current smoking, physical activity, and BMI. Model 3 included all 
of the variables in model 2 plus history of stroke, history of myocardial infarction, total and 
HDL-cholesterol, and taking ≥3 or more classes of antihypertensive medication. For the 
analysis of nocturnal hypertension, isolated nocturnal hypertension, and non-dipping pattern, 
a fourth model (model 4) included adjustment for daytime SBP. In a sensitivity analysis, we 
defined masked hypertension as non-elevated clinic BP with elevated daytime BP and/or 
elevated nighttime BP and we calculated PRs for masked hypertension associated with 
diabetes using this definition. We conducted an additional sensitivity analysis after 
calibrating the RZS BP measurements to and an AOD device. All variables with missing 
data were imputed with 10 data sets using chained equations.18 The percentage of data 
missing for each variable included in the analysis was 0.4% for education, 0.2% for marital 
status, 0.7% for current smoking, 8.8% for total cholesterol, and 9.0% for HDL-cholesterol. 
All analyses were conducted using STATA/IC 13 (Stata Corporation, College Station, 
Texas).
RESULTS
Of the 567 participants included in this analysis, the mean age was 62.3 years and 71.8% 
were female. Overall, 196 (34.6%) participants had diabetes. BMI was higher and HDL-
cholesterol was lower among participants with versus without diabetes (Table 2). 
Participants with diabetes were more likely than their counterparts without diabetes to be 
taking 3 or more classes of antihypertensive medication (31.6% versus 17.8%). Mean 24-
hour, daytime, and nighttime SBP were higher and mean clinic DBP was lower among 
participants with compared to their counterparts without diabetes.
Elevated Mean Clinic and/or Daytime BP
The prevalence of clinic and sustained hypertension was similar among participants with 
compared to without diabetes (Table 3). Diabetes was associated with a higher prevalence of 
daytime hypertension. This association remained present after full multivariable adjustment.
Diurnal BP Patterns
The prevalence of nocturnal hypertension and isolated nocturnal hypertension were higher 
among participants with compared to without diabetes (Table 4). The associations for 
nocturnal hypertension and isolated nocturnal hypertension remained statistically significant 
after age and sex adjustment and further adjustment for education, marital status, current 
smoking, physical activity, BMI, history of stroke, history of myocardial infarction, and total 
and HDL-cholesterol. These associations were attenuated after adjustment for daytime SBP. 
The prevalence of non-dipping was similar among participants with and without diabetes.
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Mismatch Between Clinical Hypertension and Out-of-Clinic Hypertension Status
The prevalence of white coat hypertension was lower for participants with compared to 
those without diabetes (25.5% versus 35.5%, Table 5). In contrast, the prevalence of masked 
hypertension and masked isolated nocturnal hypertension were higher among participants 
with compared to without diabetes. Diabetes was associated with a higher prevalence of 
masked hypertension and masked isolated nocturnal hypertension after multivariable 
adjustment. In a sensitivity analysis, diabetes was associated with an increased prevalence of 
masked hypertension when defined by non-elevated clinic BP with elevated daytime BP 
and/or elevated nighttime BP (Supplemental Table 1).
Calibrated BP
The prevalence and prevalence ratios for diabetes associated with clinic, sustained, white 
coat, masked, and masked isolated nocturnal hypertension were similar when using BP 
measurements from the RZS device and BP calibrated to an AOD (Supplemental Table 2).
DISCUSSION
In the current study, the prevalence of daytime hypertension, masked hypertension, and 
masked isolated nocturnal hypertension was higher among participants with compared to 
their counterparts without diabetes. In contrast, white coat hypertension, a phenotype that 
has not been consistently associated with increased CVD risk in most prior studies, was less 
prevalent among participants with diabetes.19 Overall, these data suggest that ABPM may 
provide information on BP beyond that obtained from measurements taken in the clinic 
setting.
Previous analyses have reported differences in BP phenotypes assessed by ABPM among 
individuals with compared to their counterparts without diabetes, including those taking and 
not taking antihypertensive medication.11,20 Gorostidi and colleagues reported higher mean 
daytime SBP (135.4 versus 131.8 mm Hg), nighttime SBP (126.0 versus 121.0 mm Hg), and 
24-hour SBP (133.0 versus 129.0 mm Hg) among hypertensive individuals with versus 
without diabetes.11 Additionally, the prevalence of a non-dipping BP was more common 
among hypertensive individuals with diabetes (64.2%) compared to their counterparts 
without diabetes (51.6%). This study was restricted to a population with a clinical indication 
for ABPM, did not include African Americans, and results were not presented after 
adjustment for potential confounders. In the current study, we found a similar prevalence of 
non-dipping pattern among participants with versus without diabetes. The prevalence of 
non-dipping BP was high in both groups which is consistent with this pattern being more 
common among African Americans.21 In IDACO, masked hypertension was more common 
in participants with versus without diabetes (29.3% versus 18.8%), consistent with our 
findings.20 However, these aforementioned studies did not include African Americans. 
African Americans are more likely than whites to have many BP phenotypes assessed by 
ABPM, including masked hypertension, nocturnal hypertension and non-dipping BP.22,23 
The current study extends findings of prior studies to a large sample of African Americans 
with a high prevalence of diabetes.
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Studies have shown that out-of-office BP have stronger associations with CVD outcomes 
when compared with clinic BP among individuals with diabetes.24,25 In a prospective study 
of 607 individuals with diabetes, a stronger association was present between mean asleep 
SBP with CVD events (hazard ratio: 1.71, 95% CI: 1.45–2.01 for each standard deviation 
higher mean asleep SBP) compared to mean clinic SBP (hazard ratio: 1.44, 95% CI: 1.19–
1.74 for each standard deviation higher mean clinic SBP).24 In a separate study of 565 
individuals with diabetes, daytime and nighttime SBP were associated with an increased risk 
of CVD events (hazard ratio: 1.45, 95% CI: 1.17–1.80 for 15 mm Hg higher daytime and 
hazard ratio: 1.37, 95% CI: 1.12–1.67 for each 17 mm Hg higher nighttime SBP), while 
CVD risk was not increased at higher clinic SBP (hazard ratio: 1.16, 95% CI: 0.91–1.48, for 
each 17 mm Hg higher clinic SBP).25 Given the stronger association of BP assessed by 
ABPM versus clinic BP with CVD morbidity, further evaluating BP phenotypes assessed by 
ABPM in relation to CVD outcomes among individuals with diabetes may provide 
important information for guiding treatment this population.
Recent guidelines by the UK National Institute for Health and Clinical Excellence (NICE) 
and US Preventive Services Task Force (USPSTF) suggest that the diagnosis of clinic 
hypertension be confirmed using ABPM in efforts to avoid misdiagnosis and 
overtreatment.26,27 However, the NICE and USPSTF recommendations are focused on 
diagnosing hypertension in untreated individuals and they did not mention recommendations 
for treated populations. The European Society of Hypertension (ESH) recommends the use 
of ABPM in individuals with diabetes for the identification of masked hypertension.28 In a 
more recent position paper, the ESH highlighted the usefulness of ABPM in identifying non-
dipping patterns and nocturnal hypertension in individuals with diabetes as these phenotypes 
are common in this population.6 In the current study the prevalence of masked and nocturnal 
hypertension were high, which supports the ESH recommendations for ABPM in individuals 
with diabetes.
The current study has several strengths, including the collection of ABPM and clinic BP 
following standardized protocols. Few population-based studies have conducted ABPM in 
African Americans and those that did had small sample sizes. This study included a large 
population-based sample of African Americans with ABPM data. A large number of 
covariates were collected as part of the JHS, allowing us to adjust for multiple potential 
confounders. Despite these strengths, the findings from this study should be interpreted in 
the context of known and potential limitations. Data were collected between 2000–2004 and 
the increased prevalence of diabetes in U.S. adults from 7.4% in 1999–2000 to 11.9% in 
2007–2008 may affect these results.29 Clinic BP was measured using a Hawksley Random 
Zero device. ABPM was only performed in a sub-sample of JHS participants. Clinic BP was 
measured at a single visit and ABPM was only performed a single time. Therefore, some 
participants’ hypertension status may have been misclassified. There were too few 
participants not taking antihypertensive medication with diabetes to study the association of 
diabetes with ABPM phenotypes in untreated individuals. However, more than 50% of US 
adults with diabetes take antihypertensive medication making this a valuable population to 
study.29
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In conclusion, in the current population-based study of African Americans taking 
antihypertensive medication, daytime, masked and masked isolated nocturnal hypertension 
were more prevalent among participants with compared to those without diabetes. Nocturnal 
hypertension was more common among participants with diabetes but this association was 
no longer present after adjustment for daytime SBP. This study highlights the high 
prevalence of ABPM phenotypes among individuals with diabetes taking antihypertensive 
medication.
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What is known about the topic
• Elevated blood pressure is a known risk factor for cardiovascular disease.
• Compared to clinic blood pressure measurements, ambulatory blood pressure provides a better 
estimate of mean blood pressure.
• In a previous study, adults with versus without diabetes were more likely to have higher daytime 
and nighttime systolic blood pressure.
What this study adds
• Among African Americans taking antihypertensive medication, there is a higher prevalence of 
daytime, masked, and masked isolated nocturnal hypertension in those with compared to without 
diabetes.
• Ambulatory blood pressure monitoring may be useful for identifying adults with diabetes who 
have increased risk for cardiovascular disease-related BP phenotypes.
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Table 1
Definitions of clinic hypertension and ambulatory blood pressure monitoring phenotypes.
Phenotype Clinic Measurements ABPM Measurements
Elevated mean clinic blood pressure and/or daytime blood pressure
Clinic Hypertension Mean SBP ≥ 140 mmHg or DBP ≥ 90 
mmHg -
Daytime Hypertension - Mean daytime SBP ≥ 135 mmHg or DBP ≥ 85 mmHg
Sustained Hypertension† Mean SBP ≥ 140 mmHg or DBP ≥ 90 mmHg Mean daytime SBP ≥ 135 mmHg or DBP ≥ 85 mmHg
Diurnal blood pressure patterns
Nocturnal Hypertension - Mean nighttime SBP ≥ 120 mmHg or DBP ≥ 70 
mmHg
Isolated Nocturnal Hypertension -
Mean daytime SBP < 135 mmHg and DBP < 85 
mmHg and mean nighttime SBP ≥ 120 mmHg or DBP 
≥ 70 mmHg
Non-Dipping Pattern - Nocturnal decline in SBP ≤ 10% from daytime SBP
Mismatch between clinic and out-of-clinic hypertension
White Coat Hypertension†† Mean SBP ≥140 mmHg or DBP ≥ 90 mmHg
Mean daytime SBP < 135 mmHg and DBP < 85 
mmHg
Masked Hypertension††† Mean SBP < 140 mmHg and DBP < 90 mmHg Mean daytime SBP ≥ 135 mmHg or DBP ≥ 85 mmHg.
Masked Isolated Nocturnal 
Hypertension†††
Mean SBP < 140 mmHg and DBP < 90 
mmHg
Mean daytime SBP < 135 mmHg and DBP < 85 
mmHg and mean nighttime SBP ≥ 120 mmHg or DBP 
≥ 70 mmHg
SBP - systolic blood pressure; DBP – diastolic blood pressure; ABPM – ambulatory blood pressure monitoring
†Analyses of sustained hypertension included the full population.
††Analyses of white coat hypertension were restricted to participants with clinic hypertension.
†††Analyses of masked hypertension and masked isolated nocturnal hypertension were restricted to participants without clinic hypertension.
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Table 2
Characteristics of Jackson Heart Study participants taking antihypertensive medication by diabetes status.
No Diabetes (n = 371) Diabetes (n = 196) p-value
Age, years 62.1 (9.7) 62.8 (8.8) 0.423
Men 27.2% 30.1% 0.469
Married 52.3% 55.1% 0.524
Less than high school education 21.0% 24.5% 0.345
Current smoker 8.7% 8.7% 0.985
No physical activity 47.4% 53.1% 0.203
BMI, kg/m2 31.2 (6.2) 33.4 (6.4) <0.001
Total cholesterol, mg/dL 200.2 (35.8) 198.9 (46.1) 0.743
HDL-cholesterol, mg/dL 55.9 (16.1) 49.5 (11.9) <0.001
History of stroke 4.6% 7.7% 0.132
History of MI 5.9% 5.6% 0.878
Taking ≥3 Classes of Antihypertensive Medications 17.8% 31.6% 0.004
Clinic Blood Pressure
 SBP, mm Hg 129.3 (16.2) 130.4 (18.4) 0.471
 DBP, mm Hg 78.1 (10.2) 75.1 (10.3) 0.001
24-Hour Blood Pressure
 SBP, mm Hg 126.4 (13.0) 132.8 (14.7) <0.001
 DBP, mm Hg 74.4 (8.8) 73.6 (9.7) 0.318
Daytime Blood Pressure
 SBP, mm Hg 129.3 (12.9) 134.8 (14.4) <0.001
 DBP, mm Hg 78.0 (9.0) 76.7 (10.3) 0.143
Nighttime Blood Pressure
 SBP, mm Hg 121.2 (15.1) 129.0 (17.2) <0.001
 DBP, mm Hg 68.8 (10.1) 68.8 (10.2) 0.962
Numbers reported are mean (standard deviation) unless otherwise indicated.
BMI: body mass index; HDL: high density lipoprotein; MI: myocardial infarction; SBP: systolic blood pressure, DBP: diastolic blood pressure.
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Table 3
Prevalence ratios for clinic hypertension, daytime hypertension, and sustained hypertension associated with 
diabetes among Jackson Heart Study participants taking antihypertensive medication.
No Diabetes Diabetes
Clinic Hypertension N=371 N=196
Prevalence, n (%) 110 (29.7%) 55 (28.1%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 0.94 (0.72–1.23)
 Model 2 1 (ref) 0.93 (0.71–1.23)
 Model 3 1 (ref) 0.92 (0.70–1.22)
Daytime Hypertension N=371 N=196
Prevalence, n (%) 148 (39.9%) 96 (49.0%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.21 (1.00–1.46)
 Model 2 1 (ref) 1.26 (1.05–1.53)
 Model 3 1 (ref) 1.32 (1.09–1.60)
Sustained Hypertension N=110 N=55
Prevalence, n (%) 71 (64.6%) 41 (74.6%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.08 (0.77–1.51)
 Model 2 1 (ref) 1.07 (0.76–1.51)
 Model 3 1 (ref) 1.12 (0.78–1.60)
CI: confidence interval
See Table 1 for the definitions of clinic hypertension, daytime hypertension and sustained hypertension.
Model 1 is adjusted for age and sex.
Model 2 is adjusted for variables in Model 1 + education, marital status, current smoking, physical activity, BMI.
Model 3 is adjusted for variables in Model 2 + history of stroke, history of myocardial infarction, total and HDL-cholesterol, and taking ≥ 3 classes 
of antihypertensive medications.
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Table 4
Prevalence ratios for nocturnal hypertension, isolated nocturnal hypertension, and non-dipping pattern 
associated with diabetes among Jackson Heart Study participants taking antihypertensive medication.
No Diabetes Diabetes
Nocturnal Hypertension N=371 N=196
Prevalence, n (%) 207 (55.8%) 143 (73.0%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.29 (1.14–1.46)
 Model 2 1 (ref) 1.29 (1.14–1.46)
 Model 3 1 (ref) 1.28 (1.12–1.45)
 Model 4 1 (ref) 1.07 (0.95–1.21)
Isolated Nocturnal Hypertension N=223 N=100
Prevalence, n (%) 81 (36.3%) 52 (52.0%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.41 (1.10–1.82)
 Model 2 1 (ref) 1.36 (1.05–1.78)
 Model 3 1 (ref) 1.27 (0.97–1.66)
 Model 4 1 (ref) 1.08 (0.83–1.40)
Non-dipping Pattern N=371 N=196
Prevalence, n (%) 252 (67.9%) 143 (73.0%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.07 (0.96–1.19)
 Model 2 1 (ref) 1.03 (0.93–1.15)
 Model 3 1 (ref) 1.03 (0.92–1.15)
 Model 4 1 (ref) 1.07 (0.95–1.20)
CI: confidence interval
See Table 1 for the definitions of nocturnal hypertension, isolated nocturnal hypertension and non-dipping pattern.
Analyses of isolated nocturnal hypertension restricted to participants without elevated daytime hypertension.
Model 1 is adjusted for age and sex.
Model 2 is adjusted for variables in Model 1 + education, marital status, current smoking, physical activity, BMI.
Model 3 is adjusted for variables in Model 2 + history of stroke, history of myocardial infarction, total and HDL-cholesterol, and taking ≥ 3 classes 
of antihypertensive medications.
Model 4 is adjusted for variables in Model 3 + daytime SBP.
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Table 5
Prevalence ratios for white coat hypertension, masked hypertension, and masked isolated nocturnal 
hypertension associated with diabetes among Jackson Heart Study participants taking antihypertensive 
medication.
No Diabetes Diabetes
White Coat Hypertension N=110 N=55
Prevalence, n (%) 39 (35.5%) 14 (25.5%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 0.78 (0.47–1.31)
 Model 2 1 (ref) 0.79 (0.47–1.32)
 Model 3 1 (ref) 0.66 (0.39–1.11)
Masked Hypertension N=261 N=141
Prevalence, n (%) 77 (29.5%) 55 (39.0%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.32 (1.00–1.74)
 Model 2 1 (ref) 1.43 (1.08–1.88)
 Model 3 1 (ref) 1.46 (1.11–1.93)
Masked Isolated Nocturnal Hypertension N=184 N=86
Prevalence, n (%) 61 (33.2%) 42 (48.8%)
Prevalence ratio (95% CI)
 Model 1 1 (ref) 1.49 (1.11–2.00)
 Model 2 1 (ref) 1.48 (1.09–2.01)
 Model 3 1 (ref) 1.38 (1.02–1.89)
CI: confidence interval
See Table 1 for the definitions of white coat hypertension, masked hypertension and masked isolated nocturnal hypertension.
Analyses of white coat hypertension restricted to participants with elevated clinic blood pressure.
Analyses of masked hypertension restricted to participants without elevated clinic blood pressure.
Analyses of masked isolated nocturnal hypertension restricted to participants without elevated clinic blood pressure and without daytime 
hypertension.
Model 1 is adjusted for age and sex.
Model 2 is adjusted for variables in Model 1 + education, marital status, current smoking, physical activity, BMI.
Model 3 is adjusted for variables in Model 2 + history of stroke, history of myocardial infarction, total and HDL-cholesterol, and taking ≥ 3 classes 
of antihypertensive medications.
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